In this context, with acute and severe HF subsequent to an OHCA, levosimendan, administrated at an early stage during decompensation, may improve hemodynamic and cardiac recovery, thus preparing a patient for the administration of beta blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors and angiotensin-converting enzyme inhibitor/angiotensin receptor-neprilysin inhibitors [32]. This evidence concerns the gene SLC5A2 and hydrops fetalis.